Body JJ - Search Results

1

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.

Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergström B; MF 4265 Study Group. Body JJ, et al. Ann Oncol. 2003 Sep;14(9):1399-405. doi: 10.1093/annonc/mdg367. Ann Oncol. 2003. PMID: 12954579 Free article. Clinical Trial.

2

Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.

Body JJ, Lichinitser M, Tjulandin S, Garnero P, Bergström B. Body JJ, et al. Ann Oncol. 2007 Jul;18(7):1165-71. doi: 10.1093/annonc/mdm119. Epub 2007 Apr 17. Ann Oncol. 2007. PMID: 17442659 Free article. Clinical Trial.

3

Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer.

Diel IJ, Body JJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergström B; MF 4265 Study Group. Diel IJ, et al. Among authors: body jj. Eur J Cancer. 2004 Jul;40(11):1704-12. doi: 10.1016/j.ejca.2004.03.025. Eur J Cancer. 2004. PMID: 15251160 Clinical Trial.

4

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.

Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body JJ, Markopoulos C, Santini D, Diel I, Di Leo A, Cameron D, Dodwell D, Smith I, Gnant M, Gray R, Harbeck N, Thurlimann B, Untch M, Cortes J, Martin M, Albert US, Conte PF, Ejlertsen B, Bergh J, Kaufmann M, Holen I. Hadji P, et al. Among authors: body jj. Ann Oncol. 2016 Mar;27(3):379-90. doi: 10.1093/annonc/mdv617. Epub 2015 Dec 17. Ann Oncol. 2016. PMID: 26681681 Free article. Review.

5

Practical guidance for the management of aromatase inhibitor-associated bone loss.

Hadji P, Body JJ, Aapro MS, Brufsky A, Coleman RE, Guise T, Lipton A, Tubiana-Hulin M. Hadji P, et al. Among authors: body jj. Ann Oncol. 2008 Aug;19(8):1407-1416. doi: 10.1093/annonc/mdn164. Epub 2008 Apr 29. Ann Oncol. 2008. PMID: 18448451 Free article.

6

Prevention and treatment of side-effects of systemic treatment: bone loss.

Body JJ. Body JJ. Ann Oncol. 2010 Oct;21 Suppl 7:vii180-5. doi: 10.1093/annonc/mdq422. Ann Oncol. 2010. PMID: 20943612 Free article. Review.

7

Bone health in cancer: ESMO Clinical Practice Guidelines.

Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, Oudard S, Bruland Ø, Flamen P, Kurth A, Van Poznak C, Aapro M, Jordan K; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Coleman R, et al. Among authors: body jj. Ann Oncol. 2020 Dec;31(12):1650-1663. doi: 10.1016/j.annonc.2020.07.019. Epub 2020 Aug 12. Ann Oncol. 2020. PMID: 32801018 Free article. No abstract available.

8

Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients.

Huyge V, Garcia C, Alexiou J, Ameye L, Vanderlinden B, Lemort M, Bergmann P, Awada A, Body JJ, Flamen P. Huyge V, et al. Among authors: body jj. Clin Oncol (R Coll Radiol). 2010 Dec;22(10):818-27. doi: 10.1016/j.clon.2010.05.021. Epub 2010 Jun 15. Clin Oncol (R Coll Radiol). 2010. PMID: 20554438

9

Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival.

Fromigue O, Kheddoumi N, Body JJ. Fromigue O, et al. Among authors: body jj. Br J Cancer. 2003 Jul 7;89(1):178-84. doi: 10.1038/sj.bjc.6601009. Br J Cancer. 2003. PMID: 12838321 Free PMC article.

10

Tumor bone disease.

Body JJ. Body JJ. Ann Endocrinol (Paris). 2006 Apr;67(2):166-72. doi: 10.1016/s0003-4266(06)72576-8. Ann Endocrinol (Paris). 2006. PMID: 16639371 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

341 results

Search Page

Filters